Minimal impact of anticoagulant on in vitro whole blood quality throughout a 35‐day cold‐storage regardless of leukoreduction timing

There is increasing interest in leukoreduced whole blood (WB) as a transfusion product for trauma patients. In some jurisdictions, few leukoreduced filters are approved or appropriate for WB leukoreduction and quality information is therefore limited. This study assessed the impact of filtration timing of WB collected in CPDA‐1 versus CPD on in vitro quality.

[1]  S. Brunskill,et al.  The difference in potential harms between whole blood and component blood transfusion in major bleeding: a rapid systematic review and meta-analysis of RCTs , 2021, Transfusion Medicine Reviews.

[2]  R. Cardigan,et al.  A comparison of platelet function in cold‐stored whole blood and platelet concentrates , 2021, Transfusion.

[3]  V. Chinchilli,et al.  Whole blood versus component therapy for haemostatic resuscitation of major bleeding: a protocol for a systematic review and meta-analysis , 2021, BMJ Open.

[4]  S. Nicholson,et al.  Efficacy and Safety of Whole Blood Transfusion in Non-Trauma Patients. , 2021, The American surgeon.

[5]  V. Bhakta,et al.  Cold‐stored leukoreduced whole blood: Extending the time between donation and filtration has minimal impact on in vitro quality , 2021, Transfusion.

[6]  J. Holcomb,et al.  A new definition for massive transfusion in the modern era of whole blood resuscitation , 2021, Transfusion.

[7]  T. Hervig,et al.  Re‐introducing whole blood for transfusion: considerations for blood providers , 2020, Vox sanguinis.

[8]  M. Franchini,et al.  The use of whole blood in traumatic bleeding: a systematic review , 2020, Internal and Emergency Medicine.

[9]  M. Fontaine,et al.  Current state of whole blood transfusion for civilian trauma resuscitation , 2020, Transfusion.

[10]  Henry E. Wang,et al.  Whole blood transfusion versus component therapy in trauma resuscitation: a systematic review and meta‐analysis , 2020, Journal of the American College of Emergency Physicians open.

[11]  T. Hervig,et al.  Cold‐stored leukoreduced CPDA‐1 whole blood: in vitro quality and hemostatic properties , 2020, Transfusion.

[12]  W. Dorlac,et al.  Effects of whole blood leukoreduction on platelet function and hemostatic parameters , 2019, Transfusion medicine.

[13]  B. Long,et al.  Whole Blood in Trauma: A Review for Emergency Clinicians. , 2019, The Journal of emergency medicine.

[14]  Parvez M Lokhandwala,et al.  Hemostatic properties of cold‐stored whole blood leukoreduced using a platelet‐sparing versus a non–platelet‐sparing filter , 2019, Transfusion.

[15]  M. A. Meledeo,et al.  Optimizing whole blood storage: hemostatic function of 35‐day stored product in CPD, CP2D, and CPDA‐1 anticoagulants , 2019, Transfusion.

[16]  Shawn C. Nessen,et al.  Whole Blood Transfusion. , 2018, Military medicine.

[17]  D. Devine,et al.  Pathogen inactivation treatment of plasma and platelet concentrates and their predicted functionality in massive transfusion protocols , 2017, Transfusion.

[18]  D. Devine,et al.  Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method , 2015, Transfusion.

[19]  R. C. Dennis,et al.  Viability and function of red blood cell concentrates stored at 4 degrees C for 35 days in CPDA‐1, CPDA‐2, or CPDA‐3 , 1982, Transfusion.